Kyverna Therapeutics, Inc.
KYTXDrugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
4
Next Catalyst
Mar 15, 2026
5wMarket Overview
Stock performance and market intelligence
4 upcoming, 1 past
Standard lymphodepletion regimen Phase 2 Results Expected
Primary completion for Standard lymphodepletion regimen trial (NCT06400303) in Systemic Sclerosis
SourceKYV-101 Phase 2 Results Expected
Primary completion for KYV-101 trial (NCT06400303) in Systemic Sclerosis
SourceStandard lymphodepletion regimen Phase 2 Results Expected
Primary completion for Standard lymphodepletion regimen trial (NCT06588491) in Stiff-Person Syndrome
SourceStandard lymphodepletion regimen Phase 2 Results Expected
Primary completion for Standard lymphodepletion regimen trial (NCT05938725) in Lupus Nephritis
SourceAI Predictions & Institutional Flow
Machine learning insights and smart money movement
FDA Submissions
Pending NDA/BLA submissions with predicted PDUFA dates
Drug Pipeline
Clinical development programs and drug candidates
Standard lymphodepletion regimen
Lupus Nephritis
Standard of Care Treatment
Myasthenia Gravis
KYV-101
Systemic Sclerosis
KYV-101 anti-CD19 CAR-T cell therapy
Lupus Nephritis
Anti-CD20 mAB
Multiple Sclerosis, Primary Progressive
| Drug Name | Phase | Indication | Designations |
|---|---|---|---|
Standard lymphodepletion regimen | Phase 3 | Lupus Nephritis | - |
Standard of Care Treatment | Phase 3 | Myasthenia Gravis | - |
KYV-101 | Phase 3 | Systemic Sclerosis | - |
KYV-101 anti-CD19 CAR-T cell therapy | Phase 2 | Lupus Nephritis | - |
Anti-CD20 mAB | Phase 2 | Multiple Sclerosis, Primary Progressive | - |
Regulatory & News
Approvals, filings, and latest developments